Clinical Trials Logo

Dyslipidemia clinical trials

View clinical trials related to Dyslipidemia.

Filter by:

NCT ID: NCT03403283 Completed - Clinical trials for Diabetic Retinopathy

Dyslipidemia and Diabetic Retinopathy

D&D
Start date: January 2014
Phase:
Study type: Observational

The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.

NCT ID: NCT03401580 Withdrawn - Hypertension Clinical Trials

Efficacy of Fixed-doses of Antihypertensive and Statin Drugs

Start date: January 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of different fixed-dose combination of Viena II in treatment of hypertension and dyslipidemia.

NCT ID: NCT03267329 Completed - Hypertension Clinical Trials

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

Start date: September 11, 2017
Phase: Phase 4
Study type: Interventional

This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.

NCT ID: NCT03235362 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706

Start date: August 7, 2017
Phase: Phase 1
Study type: Interventional

This is a phase 1, open label, multiple-dose, crossover clinical trial to investigate the pharmacokinetic drug interaction between YHR1705 and YHR1706 in healty male volunteers

NCT ID: NCT03210649 Completed - Dyslipidemia Clinical Trials

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Start date: March 7, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519

NCT ID: NCT03210532 Completed - Hypertension Clinical Trials

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

Start date: October 7, 2016
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia

NCT ID: NCT03203915 Completed - Obesity Clinical Trials

Metabolic Response to Chardonnay Grape Marc Powder

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

To determine if the addition of chardonnay grape marc (also called pomace) powder enriched with grape seed extract to the diet will result in reducing blood levels of cholesterol or triglycerides.

NCT ID: NCT03191227 Completed - Obesity Clinical Trials

The Cork and Kerry Diabetes and Heart Disease Study (Phase II) Mitchelstown Cohort

Mitchelstown
Start date: April 2010
Phase: N/A
Study type: Observational [Patient Registry]

The aim of the Cork and Kerry Study Phase II (Mitchelstown cohort recruited 2010-11) is to provide an updated profile of glucose tolerance status, cardiovascular health and their related factors in an Irish adult general population sample and to compare the findings with those obtained during baseline assessment of Phase I of the Cork and Kerry study (1998) and the rescreen (2008).

NCT ID: NCT03156842 Completed - Dyslipidemia Clinical Trials

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

FIRST
Start date: May 29, 2017
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.

NCT ID: NCT03080935 Terminated - Dyslipidemia Clinical Trials

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Start date: March 13, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118). Approximately 1600 subjects will be enrolled in this study. This study will continue for 260 weeks (approximately 5 years).